Skip to content
MarketScale
‹ Back to IndustriesHealthcare

Using Open-Source Software to Drive Reliability and Security in Lab & Life Sciences

Open-Source software’s flexibility through its distribution with the source code gives programmers the power to modify and distribute with its original rights. That versatility allows many technological innovations within the Health and Life Science space. Intel partners with Health and Life Science organizations on a wide range of solutions, and open-source is critical to…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from Intel on MarketScale.

Share

Get featured

Want to get featured in MarketScale Healthcare?

Create a free MarketScale workspace and get your company's expertise featured across our Healthcare coverage. No credit card, no demo required.

Start free

Open-Source software’s flexibility through its distribution with the source code gives programmers the power to modify and distribute with its original rights. That versatility allows many technological innovations within the Health and Life Science space. Intel partners with Health and Life Science organizations on a wide range of solutions, and open-source is critical to bringing new advancements to life. 

Health and Life Science at the Edge’s Morgan Andersen welcomed Intel Product Manager Amy Gilliam and Director of Security Communications Christopher Robinson for a discussion on open-source, everything from what it is, what the culture is like, and managing the quality of the code.

Gilliam says the culture around open source has grown to become a collaborative environment that’s enhanced over the years. Open exchange, de-centralized coding collaboration and peer review are all norms that move open source in a positive direction. “Peer review is a huge part of the open-source development process, in which developers submit code, it gets reviewed by multiple team members and project members before it gets integrated into the main code base by the maintainer,” Gilliam adds. 

From Robinson’s perspective, open source thrives because of the collaboration community. “I’ve been doing security in upstream open source for just under a decade, and I get to work with people from all around the world. We used to have a concept frequently talked about; it was called meritocracy; whereas you were contributing to these communities, people would put forth other ideas, and normally the best idea will win out. After much review and conversation, you’ll generally have better quality code because you’ve had all these different types of inputs.” 

So, how does security factor into open source when privacy is critical to a lot of work done in the health and life science world? Some essential regulations and rules govern the industry to protect human life. Gilliam says technology developers must familiarize themselves with these regulations and ensure the flexibility and capability to meet those compliance requirements now and in the future. 

“The FDA requires disclosures of software submission,” Gilliam said. “So, along with those disclosures of software, are usually calling out of risks and mitigations. Those can be cybersecurity risks, privacy risks, etc. We’re monitoring for that as we’re building software and these analytical tools that will help leverage and accelerate processes in the pharmaceutical industry.” 

Learn more about Open Source solutions by connecting with Amy Gilliam and Christopher Robinson on LinkedIn or visit Intel Health and Life Sciences. 

Subscribe to this channel on Apple PodcastsSpotify, and Google Podcasts to hear more from the Intel Network and Edge Solutions Group.

Intel

Part of this channel

Intel

Silicon and AI platforms powering enterprise and edge compute.

Visit the channel

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Get your team featuredSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free plan

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Create a free workspace and see it with your own people. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale workspace, up to 10 people
One professional video edit a month for qualifying companies
Media requests to your crowd, remote recording, AI writing tools
$0, no credit card, nothing that expires

More Healthcare Insights

NICE recommends Enhertu for HER2-low advanced breast cancer in England

NICE recommends Enhertu for HER2-low advanced breast cancer in England

American Pharmaceutical Review reported that NICE has recommended Enhertu for routine NHS use in people with HER2-low advanced breast cancer, following a commercial agreement and updates to NICE’s methods under the U.K.-U.S. Pharmaceutical Pricing Agreement.

  • 01NICE tied the reversal to 2026 changes: higher cost-effectiveness thresholds that took effect in April and a new quality-of-life assessment method published Aug. 27, 2026.
  • 02Access planning still varies by nation: Fierce Pharma reported Wales requires funding within 60 days of final guidance, while Scotland and Northern Ireland follow separate processes.

Sep 21, 2026

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly’s $6.5B Houston Bet Highlights U.S. Pharma Reshoring

Eli Lilly has broken ground on a $6.5 billion manufacturing facility in Houston, slated for completion around 2030. While attention has focused on scaling production of Foundayo, its oral GLP-1 treatment, the project also reflects broader U.S. efforts to rebuild domestic pharmaceutical manufacturing and highlights the supply chain challenge of forecasting demand and building capacity years in advance.

  • 01Eli Lilly commits $6.5 billion to a Houston pharmaceutical manufacturing facility due for completion around 2030, one of the largest single U.S. pharma production investments in recent years
  • 02GLP-1 demand forecasting remains highly uncertain, making it difficult to commit billions to manufacturing capacity years before demand and required output are clear.
  • 03Houston's selection reflects industrial capacity and workforce depth, positioning the region as a biomanufacturing corridor and creating long-term hiring demand in engineering, quality control, and skilled trades

Sep 21, 2026

NextGen Invent’s Deepak Mittal argues for scoped healthcare AI pilots with early governance

NextGen Invent’s Deepak Mittal argues that healthcare AI pilots can begin with a reliable data subset and early governance. His performance figures are vendor claims, not independently verified results.

  • 01Deepak Mittal advocates starting with a defined problem and suitable data rather than waiting for perfect organization-wide data.
  • 02Some performance figures cited in the interview (for example, preparation time and model counts) are company-reported and not independently verified in this article.
  • 03NIST’s voluntary AI Risk Management Framework provides an independent structure for governance and risk evaluation.

Sep 21, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512